Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

A Comparison of Three Child OHRQoL Measures.

Foster Page L, Gilchrist F, Broder HL, Clark E, Thomson WM.

Dent J (Basel). 2019 Feb 12;7(1). pii: E19. doi: 10.3390/dj7010019.

2.

Ube3a reinstatement mitigates epileptogenesis in Angelman syndrome model mice.

Gu B, Carstens KE, Judson MC, Dalton KA, RougiƩ M, Clark EP, Dudek SM, Philpot BD.

J Clin Invest. 2019 Jan 2;129(1):163-168. doi: 10.1172/JCI120816. Epub 2018 Nov 19.

3.

Characterization and structure-activity relationships of indenoisoquinoline-derived topoisomerase I inhibitors in unsilencing the dormant Ube3a gene associated with Angelman syndrome.

Lee HM, Clark EP, Kuijer MB, Cushman M, Pommier Y, Philpot BD.

Mol Autism. 2018 Aug 17;9:45. doi: 10.1186/s13229-018-0228-2. eCollection 2018.

4.

Common Pathophysiology in Multiple Mouse Models of Pitt-Hopkins Syndrome.

Thaxton C, Kloth AD, Clark EP, Moy SS, Chitwood RA, Philpot BD.

J Neurosci. 2018 Jan 24;38(4):918-936. doi: 10.1523/JNEUROSCI.1305-17.2017. Epub 2017 Dec 8.

5.

The future of anticoagulation.

Chataway J, Lichten C, Clark E.

Future Cardiol. 2016 Jan;12(1):5-7. doi: 10.2217/fca.15.75. Epub 2015 Dec 21. No abstract available.

6.

Responsiveness of 2 scales to evaluate lateropulsion or pusher syndrome recovery after stroke.

Clark E, Hill KD, Punt TD.

Arch Phys Med Rehabil. 2012 Jan;93(1):149-55. doi: 10.1016/j.apmr.2011.06.017.

PMID:
22200395

Supplemental Content

Loading ...
Support Center